KITLG and glioblastoma: As Figure 3B shows, the median OS of the GBM patients at the SCF <2.80 ng/ml and SCF ≥2.80 ng/ml groups was 17.5 months (95% CI, 11.8–25.1 months) and 17.1 months (95% CI, 12.5–24.6 months), respectively.